8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Ocugen, Inc.(OCGN)Earnings, Financials & Key Ratios
OCGN•NASDAQ
$1.50
Price updated Jul 7, 2026
AboutOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.Show more
- Revenue$4M+8.8%
- EBITDA-$61M-14.7%
- Net Income-$68M-25.5%
- EPS (Diluted)-0.23-15.0%
- Gross Margin45.86%-10.9%
- EBITDA Margin-1371.56%-5.4%
- Operating Margin-1425.7%-5.6%
- Net Margin-1537.41%-15.3%
- ROE-776.89%-404.4%
OCGN Price & Volume
Ocugen, Inc. (OCGN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Pipeline Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent Capital Exhaustion Risk
Key Thesis Takeaways
- Ocugen's valuation remains tethered to a high-risk, unproven modifier gene therapy platform that lacks a stable, product-driven commercial revenue stream.
- The company's reliance on non-recurring milestone payments and aggressive stock-based compensation creates significant uncertainty regarding long-term solvency.
- Investors should monitor the rapid erosion of the liquidity buffer as the firm continues to fund intensive Phase 3 clinical trials amidst widening operational deficits.
Verdict Logic
the company's cash position has dwindled to $31.9M as of 2026Q1, representing a significant decline from the $58.5M reported in 2024Q4, which suggests an imminent risk of capital exhaustion.
OCGN Growth Metrics
Ocugen, Inc. (OCGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years152.5%
3 Years21.05%
TTM-1.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.67%
Return on Capital
10 Years-128.28%
5 Years-110.58%
3 Years-119.53%
Last Year-154.72%
OCGN Recent Earnings
Ocugen, Inc. (OCGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (86%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.06-20.0%
$0.05
Rev
$2M+266.9%
$417,833
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
$193,000-118.0%
$1M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.07-21.7%
$0.06
Rev
$2M+298.2%
$440,000
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$1M+357.7%
$300,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.05-20.0% | $2Mvs $417,833+266.9% |
| Q2 2026 | Mar 4, 2026 | $0.06vs $0.06+0.0% | $193,000vs $1M-118.0% |
| Q4 2025 | Nov 5, 2025 | $0.07vs $0.06-21.7% | $2Mvs $440,000+298.2% |
| Q3 2025 | Aug 1, 2025 | $0.05vs $0.06+16.7% | $1Mvs $300,000+357.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Ocugen, Inc. (OCGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.50 | $507.78M | -6.52 | 8.83% | -1537.41% | -776.89% | — | |
| $11.51 | $966.21M | -3.41 | — | — | -128.57% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — |
Compare OCGN vs Peers
Ocugen, Inc. (OCGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCGN SEC Filings & Documents
Ocugen, Inc. (OCGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OCGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OCGN Frequently Asked Questions
Ocugen, Inc. (OCGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Ocugen, Inc.'s revenue?
Ocugen, Inc. (OCGN) reported $4.5M in revenue for fiscal year 2025. This represents a 17073% increase from $0.0M in 2012.
How fast is Ocugen, Inc. growing?
Ocugen, Inc. (OCGN) grew revenue by 8.8% over the past year. This is steady growth.
Is OCGN profitable?
Ocugen, Inc. (OCGN) reported a net loss of $71.7M for fiscal year 2025.
Dividend & Returns
What is OCGN's return on equity?
Ocugen, Inc. (OCGN) has a return on equity (ROE) of -776.9%. Negative ROE indicates the company is unprofitable.
What is Ocugen, Inc.'s free cash flow?
Ocugen, Inc. (OCGN) had negative free cash flow of $59.6M in fiscal year 2025, likely due to heavy capital investments.